1. Pitfalls in the Interpretation of Pharmacoeconomic Studies

   • Norman M. Kaplan

   Leading Article 13 November 2012 Pages: 303 - 305

2. Evaluation of Pharmaceutical Innovation

   • Selwyn St Leger
   • Kathleen Rowsell
   • Alan Haycox

   Leading Article 13 November 2012 Pages: 306 - 311

3. Economic Costs of Functional Dyspepsia

   • Olof Nyrén
   • Greger Lindberg
   • Rein Seensalu

   Review Article 13 November 2012 Pages: 312 - 324

4. Economic Evaluation of Drug Therapy

   • Magnus Johannesson
   • Per-Olov Johansson
   • Bengt Jönsson

   Review Article 13 November 2012 Pages: 325 - 337

5. Preference Based Outcome Measures for Economic Evaluation of Drug Interventions

   • Abraham Mehrez
   • Amiram Gafni

   Review Article 13 November 2012 Pages: 338 - 345

6. A Comparison of the Costs and Benefits of Recombinant Human Erythropoietin (Epoetin) in the Treatment of Chronic Renal Failure in 5 European Countries

   • Brenda Leese
   • John Hutton
   • Alan Maynard

   Review Article 13 November 2012 Pages: 346 - 356

7. Comparison of the Cost-Effectiveness of Various Therapies for Common Prostatic Disorders

   • Elizabeth A. Amin
   • Mohammad Amin

   Review Article 13 November 2012 Pages: 357 - 369

8. Clinical Economics

   • Catherine Copley-Merriman
   • Lisa Egbuonu-Davis
   • Kati Copley-Merriman

   Original Research Article 13 November 2012 Pages: 370 - 376

9. Drug Cost Containment at a Large Teaching Hospital

   • Peter I. Pillans
   • Ian Conry
   • Barbara E. Gie

   Original Research Article 13 November 2012 Pages: 377 - 382

10. Acceptable Usage of the Term ‘Cost-Effective’

    • Richard J. Grant

    Current Comment 13 November 2012 Pages: 383 - 384